Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02415881 · ClinicalTrials.gov registry record · Phase 1
Panitumumab IRDye800 Optical Imaging Study
A Phase 1 study, sponsored by Eben Rosenthal.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT02415881: Completed Phase 1 study, sponsored by Eben Rosenthal.
NCT02415881 is a Phase 1 study that has completed, run by Eben Rosenthal. The registered enrollment target is 64 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02415881, a Phase 1 study, has completed, sponsored by Eben Rosenthal.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
Phase I trial to evaluate the safety of escalating dose levels of conjugated panitumumab-IRDye800 in subjects with head and neck squamous cell carcinoma (HNSCC) that undergo surgery with curative intent.
Primary Outcome
Safety profile of panitumumab conjugated to IRDye800CW (panitumumab IRDye800) will be measured by assessing number of Grade 2 or higher adverse events which have been determined to be clinically significant and definitely, probably or possibly related.
Interventions
- DRUG Panitumumab IRDye 800
- DEVICE da Vinci Firefly
- DEVICE IMAGE1 + ICG Hopkins telescope and/or VITOM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2016-08 |
| Est. Completion | 2021-09-21 |
| Phase | Phase 1 |
What the finished NCT02415881 record still lists
NCT02415881 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which Panitumumab IRDye 800 is the first listed.
NCT02415881 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02415881 about?
NCT02415881 is a clinical study titled "Panitumumab IRDye800 Optical Imaging Study". Phase I trial to evaluate the safety of escalating dose levels of conjugated panitumumab-IRDye800 in subjects with head and neck squamous cell carcinoma (HNSCC) that undergo surgery with curative intent.
What is the current status of trial NCT02415881?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2016-08. Estimated completion is 2021-09-21.
What interventions are being tested in trial NCT02415881?
The interventions under investigation include: Panitumumab IRDye 800 (DRUG), da Vinci Firefly (DEVICE), IMAGE1 + ICG Hopkins telescope and/or VITOM (DEVICE).
Who is sponsoring clinical trial NCT02415881?
This trial is sponsored by Eben Rosenthal, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02415881's enrollment target sits among peer trials
64 808th of 2000 higher than 1,181 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia